Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant doxorubicin-loaded prostatic arterial embolization before radical prostatectomy in high-risk prostate cancer
2019-001920-36Phase 2Terminated
- Sponsor
- CHU Nîmes
- Start
- Sep 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in prostate cancer (PCa), sponsored by CHU Nîmes. Primary endpoint: Serious adverse events with non-target necrosis. Started Sep 2019; status: terminated.
02
Drugs
doxorubicin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2019-001920-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001920-36.